WeVote
Log In

Bill

Bill

S 96

An Act relative to THC potency limits for types of marijuana

194th Legislature (2025-2026) Introduced by John Keenan and 1 co-sponsor

Massachusetts bill caps THC potency in marijuana products to reduce health risks and regulate the legal cannabis market.

Accompanied a study order, see S2677
0
WeVote Research Nonpartisan
Bill Summary · S 96

Legislative bill overview

S 96 proposes to establish legal limits on the tetrahydrocannabinol (THC) potency levels permitted in different types of marijuana products sold in Massachusetts. The bill would create a regulatory framework to cap THC concentrations across cannabis categories, likely including flower, concentrates, edibles, and other forms. This represents a significant modification to Massachusetts' current cannabis regulations, which do not impose such potency caps.

Why is this important

THC potency in legal cannabis products has increased substantially over the past decade, with some concentrates exceeding 90% THC compared to historical averages of 5-15% in flower. This matters because higher potency products are associated with increased risks of cannabis use disorder, acute psychiatric symptoms, and potentially impaired driving. Potency limits would affect product availability, consumer choice, tax revenue from cannabis sales, and the competitive landscape between legal and illicit markets.

Potential points of contention

  • Medical vs. recreational use distinction: Unclear whether potency limits would apply equally to medical marijuana patients who may require higher-potency products for symptom management
  • Market competitiveness and revenue: Potency caps could reduce product diversity and potentially drive consumers toward illicit markets offering higher-potency alternatives, impacting state tax revenue
  • Enforcement and compliance burden: Establishing and monitoring potency limits would require enhanced testing infrastructure and regulatory resources, raising implementation costs
  • Scientific basis for specific thresholds: Disagreement may exist over what potency levels are appropriately evidence-based versus arbitrary

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.